Stay ahead in the competitive pharmaceutical industry with in-depth insights into the Hepatitis B pipeline. See the latest advancements, the leading Hepatitis B companies driving innovation, and the most promising new drugs shaping the future of treatment. Download our comprehensive report now to explore the clinical-stage developments and strategic collaborations that are transforming the industry. @Hepatitis B Pipeline Outlook Report
Key Takeaways from the Hepatitis B Virus Pipeline Market
March 2025: Shanghai-based Yoltek Therapeutics announces promising results from the ongoing investigator-initiated clinical trial of YOLT-203 for patients with primary hyperoxaluria type 1 (PH1).
DelveInsight's Hepatitis B Virus pipeline report highlights a robust landscape, with over 80 active players developing over 90 pipeline treatments for Hepatitis B Virus.
Major companies in the Hepatitis B virus include:
Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceutical, Pharma Essentia, Jiangsu Hengrui Pharmaceutical, Enanta Pharmaceutical, Zhongkundan Pharmaceutical, Guangzhou Luxeon Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceutical, Altimmune, Viravax, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, Prism Pharma, Hepion Pharmaceutical, Hepatera, Virion Therapeutics, and others.Promising Hepatitis B virus treatments include: tenofovir disoproxil fumarate, HBVAXPRO 5µg, pegylated interferon alfacon-2, bepirovirsen, daproxiran/tomurigisiran dose level 1, and many more.
Uncover Hepatitis B Virus groundbreaking developments in the drug pipeline in our latest report. Get exclusive insights into Hepatitis B Virus clinical trials, regulatory updates, and emerging medicines across multiple therapeutic areas. Learn how leading Hepatitis B Virus companies are positioning themselves for success in the evolving pharmaceutical market. Access the full report now!" @Evaluation of clinical trials for hepatitis B virus
New Drug Profile for Hepatitis B Virus
Bepirovirsen – GSK
Bepirovirsen is an investigational antisense oligonucleotide (ASO) designed to specifically recognize HBV RNA, prevent replication, and reduce viral antigens (proteins) that maintain chronic infection. ASO recruits liver enzymes that degrade viral RNA, leading to reduced infectivity of HBV DNA and antigen levels in the bloodstream. Bepirovirsen also stimulates an immune response via Toll-like receptor 8 (TLR8), potentially allowing for long-term viral clearance.
VIR-2218 - for biotechnology
VIR-2218 is a subcutaneously administered HBV-targeting siRNA with potential immune stimulatory and antiviral activity. Leveraging Enhanced Stabilization Chemistry Plus (ESC+) technology, it provides increased stability and minimizes off-target activity. Currently in Phase II trials, VIR-2218 is the first siRNA from Vir Biotechnology in partnership with Alnylam Pharmaceuticals to participate in clinical trials.
AB-729 - Arbutus Biopharma
AB-729 is an RNA interference (RNAi) therapy designed to reduce all HBV viral antigens, including Hepatitis B surface antigen (HBsAg), which is key to restoring an immune response. Using N-acetylgalactosamine (GalNAc) conjugation technology, AB-729 targets liver cells. It is currently being tested in a Phase IIa trial in combination with nucleoside analog therapy and Peg-IFNα-2a in chronic HBV patients.
AHB-137 - Osper Biopharma
AHB-137 is designed as a non-binding antisense oligonucleotide (ASO) as a potential backbone for the functional cure of chronic hepatitis B (CHB). In June 2023, the China Center for Drug Evaluation (CDE) approved it for the Investigational New Drug (IND) application. With high antiviral potency, good pharmacokinetics, and a strong safety profile, AHB-137 is currently in Phase I trials.
Hepatitis B Virus Pipeline Insights
The report provides:
Detailed insights into companies developing HBV treatments.
Segment treatment candidates into early, mid, and late stages of development.
HBV companies evaluate active and inactive (dormant/discontinued) projects.
HBV drugs are classified as follows: stage of development, route of administration, target receptor, monotherapy/combination therapy, mechanism of action, and type of molecule.
Analyzing the collaborations, licensing agreements, and financial investments shaping the future of HBV drug development.
Explore the dynamic world of drug development with our latest Hepatitis B Virus Pipeline Insights report. From early-stage research to late-stage Hepatitis B Virus clinical trials, our analysis covers leading Hepatitis B Virus companies, innovative treatment approaches, and the next wave of novel medicines. Don't miss out! Download now to stay up to date. @Hepatitis B Virus Treatment
Hepatitis B virus companies
Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceutical, Pharma Essentia, Jiangsu Hengrui Pharmaceutical, Enanta Pharmaceutical, Zhongkundang Pharmaceutical, Guangzhou Luxeon Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceutical, Altimmune, Viravax, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, Prism Pharma, Hepion Pharmaceutical, Hepatera, Virion Therapeutics, and many more!
Evaluation of Hepatitis B Virus Therapy by Route of Administration
Oral
Intravenous
Subcutaneous
Parenteral
Hot Topic
Treatment evaluation of hepatitis B virus by molecular type
Recombinant fusion proteins
Low molecular weight
Monoclonal antibodies
peptide
polymer
Gene Therapy
The future of healthcare is rapidly evolving! Get detailed insights into ongoing Hepatitis B Virus clinical trials, leading companies driving innovation, and the most promising new drugs in the pipeline. Stay up to date with the latest Hepatitis B Virus pipeline insights. Download the report to take a closer look at the next generation of treatments. @Hepatitis B Virus Market Drivers, Barriers, and Future Outlook
Hepatitis B Virus Pipeline Market Scope
Scope – Global
Hepatitis B Virus Company -Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceutical, Pharma Essentia, Jiangsu Hengrui Pharmaceutical, Enanta Pharmaceutical, Zhongkundan Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceutical, Altimune, Virabax, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, Prism Pharma, Hepion Pharmaceutical, Hepatella, Virion TherapeuticsAnd more.
Hepatitis B Virus Treatment -Tenofovir disoproxil fumarate, HBVAXPRO 5µg, peginterferon alfacon-2, bepirovirsen, daprsiran/tomurigisiran dose level 1,others.
Hepatitis B Virus Treatment Evaluation by Product Type: Mono, Combination, and Mono/Combination
Hepatitis B virus therapy evaluation by clinical phase: discovery, preclinical, phase I, phase II, phase III
Which new Hepatitis B Virus drugs will revolutionize the treatment landscape? Which Hepatitis B Virus companies are leading the way in drug discovery? Find the answers in our latest Hepatitis B Virus Pipeline Insights report, which offers in-depth coverage of clinical trials, regulatory developments, and upcoming breakthroughs. Download now and stay at the forefront of pharmaceutical innovation!" @New Hepatitis B Drugs and Companies
table of contents
introduction
executive summary
Hepatitis B virus infection: an overview
Pipeline Therapeutics
Therapeutic evaluation
Hepatitis B Virus Infection – A DelveInsight Analytical Perspective
Late Stage Products (Phase III)
Bepirovirsen: GSK
Drug profile in detailed report…..
Mid-stage products (Phase II)
FOR 2218: For Biotechnology
Drug profile in detailed report…..
Early Stage Products (Phase I)
AHB-137: Ausper Biopharmaceuticals
Drug profile in detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profile in detailed report…..
Inactive Products
Hepatitis B Virus Infection Major Companies
Key products for Hepatitis B virus infection
Hepatitis B virus infection – an unmet need
Hepatitis B Virus Infection-Market Drivers and Barriers
Hepatitis B virus infection - prospects and conclusions
Hepatitis B virus infection analyst's view
Hepatitis B Virus Infection Major Companies
appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm, providing clients with high-quality market intelligence and analytics to support informed business decisions. With an experienced team of industry experts and a deep understanding of the life sciences and healthcare sector, we deliver customized research solutions and insights to clients globally. Contact us to get high-quality, accurate, real-time intelligence to stay ahead of the growth curve.
Contact Information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
